Plus Therapeutics Q2 FY26 net loss widens to $9.01 million; operating loss widens to $9.06 million
PSTV•Grant revenue declines while cash position is steady
Grant revenue fell 70.43% to $411,000, reflecting lower CPRIT support for REYOBIQ in leptomeningeal metastases.
Cash, cash equivalents and investments totaled $8.6 million at June 30, unchanged from Dec. 31.
The company said it was rebranded as Cerenome effective Aug. 3, and that REYOBIQ trial enrollment continued, with ReSPECT-GBM data expected in Q1 2027.
Quarterly loss widens on higher commercialization and trial spending
Plus Therapeutics posted a Q2 net loss of $9.01 million, or $1.31 a share, swinging from net income of $5.2 million.
Operating loss widened to $9.06 million from $1.5 million, driven by expanded CNSide commercialization and REYOBIQ Phase 2 spending.
